- Home
- CCII vs ENTA Comparison
CCII vs ENTA Comparison
Compare CCII & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCII
- ENTA
- Stock Information
- Founded
- CCII 2024
- ENTA 1995
- Country
- CCII United States
- ENTA United States
- Employees
- CCII N/A
- ENTA N/A
- Industry
- CCII
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- CCII
- ENTA Health Care
- Exchange
- CCII Nasdaq
- ENTA Nasdaq
- Market Cap
- CCII 359.1M
- ENTA 316.2M
- IPO Year
- CCII 2025
- ENTA 2013
- Fundamental
- Price
- CCII $10.20
- ENTA $12.70
- Analyst Decision
- CCII
- ENTA Strong Buy
- Analyst Count
- CCII 0
- ENTA 6
- Target Price
- CCII N/A
- ENTA $20.33
- AVG Volume (30 Days)
- CCII 96.0K
- ENTA 387.8K
- Earning Date
- CCII 01-01-0001
- ENTA 11-17-2025
- Dividend Yield
- CCII N/A
- ENTA N/A
- EPS Growth
- CCII N/A
- ENTA N/A
- EPS
- CCII N/A
- ENTA N/A
- Revenue
- CCII N/A
- ENTA $65,324,000.00
- Revenue This Year
- CCII N/A
- ENTA $2.13
- Revenue Next Year
- CCII N/A
- ENTA $2.74
- P/E Ratio
- CCII N/A
- ENTA N/A
- Revenue Growth
- CCII N/A
- ENTA N/A
- 52 Week Low
- CCII $10.07
- ENTA $4.09
- 52 Week High
- CCII $10.47
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- CCII N/A
- ENTA 65.25
- Support Level
- CCII N/A
- ENTA $11.89
- Resistance Level
- CCII N/A
- ENTA $13.00
- Average True Range (ATR)
- CCII 0.00
- ENTA 0.83
- MACD
- CCII 0.00
- ENTA 0.08
- Stochastic Oscillator
- CCII 0.00
- ENTA 77.48
About CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares
Cohen Circle Acquisition Corp II is a blank check company.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.